479 related articles for article (PubMed ID: 33804869)
1. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.
Csizmar CM; Ansell SM
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804869
[TBL] [Abstract][Full Text] [Related]
2. Lymphoma Microenvironment and Immunotherapy.
Xu ML; Fedoriw Y
Surg Pathol Clin; 2016 Mar; 9(1):93-100. PubMed ID: 26940270
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
5. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
de Charette M; Houot R
Haematologica; 2018 Aug; 103(8):1256-1268. PubMed ID: 30006449
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of lymphomas.
Ansell SM; Lin Y
J Clin Invest; 2020 Apr; 130(4):1576-1585. PubMed ID: 32039913
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
8. Fundamentals of immunology for understanding immunotherapy for lymphoma.
Ansell SM
Blood Adv; 2020 Nov; 4(22):5863-5867. PubMed ID: 33232478
[TBL] [Abstract][Full Text] [Related]
9. Fundamentals of immunology for understanding immunotherapy for lymphoma.
Ansell SM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):585-589. PubMed ID: 33275742
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in aggressive B-cell lymphomas.
Jacobson CA; Armand P
Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
[TBL] [Abstract][Full Text] [Related]
11. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity.
Brandmaier A; Formenti SC
Semin Radiat Oncol; 2020 Apr; 30(2):139-144. PubMed ID: 32381293
[TBL] [Abstract][Full Text] [Related]
13. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
15. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Falchi L
Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
[TBL] [Abstract][Full Text] [Related]
16. Regulatory B cells in anti-tumor immunity.
Zhang Y; Gallastegui N; Rosenblatt JD
Int Immunol; 2015 Oct; 27(10):521-30. PubMed ID: 25999597
[TBL] [Abstract][Full Text] [Related]
17. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
18. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
[TBL] [Abstract][Full Text] [Related]
19. Vaccination strategies in lymphoproliferative disorders: Failures and successes.
Allegra A; Russo S; Gerace D; CalabrĂ² L; Maisano V; Innao V; Musolino C
Leuk Res; 2015 Oct; 39(10):1006-19. PubMed ID: 26298174
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]